To analyze the effect of Huachansu Capsules combined with apatinib on immune cells and prognosis of patients failing the second-line treatment for advanced gastric carcinoma(AGC).Methods:The clinical data of 46 patients with AGC treated with Huachansu Capsules combined with apatinib in 3201 Hospital Affiliated to Medical College of Xi'an Jiaotong University from January 2017 to December 2019 were collected.Flow cytometry was employed to measure the different immune cell subsets before and 1 month after the treatment.The progression-free survival(PFS) within 1 year after treatment was recorded，and the relationship between different immune cell subsets and PFS was analyzed.Cox regression was performed to analyze the relationship between different immune cell subsets and PFS one year after treatment.Results:After 1 month of treatment，CD4+CD25+T cells and CD4+CD25+CD127low/-Treg cells in Huachansu Capsules combined with apatinib group increased compared with those before treatment(P<0.05).During the 1-year follow-up，there were 9 patients without progression，and the median PFS was 4.5 months.After treatment，the median PFS in the patients with increased CD4+CD25+T cells was better than that in patients with reduced CD4+CD25+T cells(P<0.05).There was no significant relationship between other immune cell changes and PFS(P>0.05).One month after treatment，the decrease of CD4+CD25+T cells was the influencing factor of PFS shortening(RR=1.316，95%CI 1.057 to 1.639，P=0.015).The main adverse drug reactions were skin reactions(32，69.57%) and diarrhea(11，23.91%)，which were tolerable.Conclusion:Huachansu Capsules combined with apatinib can regulate the immune cell subsets of patients failing the second-line treatment for AGC.After 1 month of treatment，the CD4+CD25+T cell of the patients increased significantly.The patients with increased CD4+CD25+T cells had longer PFS.